Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping

J Thorac Oncol. 2017 Jul;12(7):e89-e90. doi: 10.1016/j.jtho.2017.02.017.

Authors

Alexa B Schrock¹, Andrea Lai², Siraj M Ali³, Vincent A Miller³, Luis E Raez⁴

Affiliations

¹ Clinical Development, Foundation Medicine, Inc., Cambridge, Massachusetts. Electronic address: [email protected].
² Biomedical Informatics, Foundation Medicine, Inc., Cambridge, Massachusetts.
³ Clinical Development, Foundation Medicine, Inc., Cambridge, Massachusetts.
⁴ Memorial Cancer Institute, Memorial Healthcare System, Hollywood, Florida.

PMID: 28629543
DOI: 10.1016/j.jtho.2017.02.017

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Crizotinib / pharmacology
Crizotinib / therapeutic use*
Drug Resistance, Neoplasm
Exons
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Male
Mutation

Substances

Antineoplastic Agents
Crizotinib